You are here: Industry Insights > AZD2816

News List

First patients vaccinated with AstraZeneca’s COVID-19 variant vaccine europeanpharmaceuticalreview
July 05, 2021
The Phase II/III trial will assess the safety and immunogenicity of a AstraZeneca’s novel COVID-19 variant vaccine candidate, AZD2816.
First COVID-19 Variant Vaccine Trial Participants Vaccinated americanpharmaceuticalreview
June 30, 2021
The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 have been vaccinated to assess safety and immunogenicity in both previously vaccinated and unvaccinated adults.
AZ doses first participants with COVID-19 variant vaccine pharmatimes
June 29, 2021
AstraZeneca (AZ) has announced that the first participants have been vaccinated as part of a Phase II/III trial testing a new COVID-19 variant vaccine – AZD2816.
First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated firstwordpharma
June 28, 2021
The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults.